Omnicell, Inc. (OMCL) News
Filter OMCL News Items
OMCL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OMCL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest OMCL News From Around the Web
Below are the latest news stories about OMNICELL INC that investors may wish to consider to help them evaluate OMCL as an investment opportunity.
Omnicell to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceFORT WORTH, Texas, January 08, 2025--Omnicell to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Omnicell Gains 26.2% in a Year: What's Driving the Stock?OMCL's shares rise on the back of its XT Amplify program gaining market traction with its initial offerings. However, the unfavorable macroeconomic scenario is concerning. |
Reasons to Retain Phibro Stock in Your Portfolio NowPAHC's prospering Vaccine business sparks optimism for future growth. However, headwinds such as unfavorable foreign exchange might hamper the company's operations. |
Reasons to Retain Medtronic Stock in Your Portfolio NowInvestors continue to be optimistic about MDT due to its impressive Neuroscience portfolio. Yet, the dull macroeconomic scenario poses a concern to the company's margins. |
Here's Why You Should Retain HOLX Stock in Your Portfolio NowHologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns. |
Here's Why You Should Hold IART Stock in Your Portfolio NowIntegra's growth within its Tissue Technologies business segment bolsters investors' confidence in the stock. |
Reasons to Retain AMED Stock in Your Portfolio NowAmedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry. |
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio NowVeracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors. |
Here's Why You Should Add HAE Stock to Your Portfolio NowStrong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics. |
The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott LaboratoriesVeracyte, Omnicell, Masimo and Abbott Laboratories are included in this Analyst Blog. |